Presently, there are two approved drug and over 150 product candidates, claims Roots Analysis

January 8, 2021
Kevin123987

 

Significant advancements in the developmental pipeline across various oncological disorders, infectious diseases and genetic disorders have amplified the interest of various pharmaceutical establishments and have inspired research groups across the world, to focus their efforts on the development of RNAi therapeutics. Further, there are multiple pipeline candidates in mid to late-stage (phase II and above) trials and are anticipated to enter the market over the next 5-10 years.

 

To order this 350+ page report, which features 130+ figures and 190+ tables, please visit this link

 

The USD 9.2 billion (by 2030) financial opportunity within the RNAi therapeutics market has been analyzed across the following segments:

  • Key therapeutic areas
  • Oncological disorders
  • Infectious diseases
  • Genetic disorders
  • Ophthalmic disorders
  • Hepatic disorders
  • Respiratory disorders

 

  • Type of RNAi molecule
  • siRNA
  • miRNA
  • shRNA
  • sshRNA
  • DNA

 

  • Route of administration
  • Subcutaneous
  • Intravenous
  • Intradermal
  • Intratumoral
  • Intravitreal
  • Oral
  • Intramuscular

 

  • Key geographical regions
  • North America
  • Europe
  • Asia Pacific and the Rest of the World

 

  • Leading Players

 

The RNAi Therapeutics Market (2nd Edition), 2019 – 2030: Focus on siRNA, miRNA, shRNA and DNA report features the following companies, which we identified to be key players in this domain:

  • Quark Pharmaceuticals
  • Alnylam Pharmaceuticals
  • Dicerna Pharmaceuticals
  • Souzhou Ribo Life Sciences
  • Olix Pharmaceuticals
  • Sirnaomics
  • Ariz Precision Medicine
  • Arrowhead Pharmaceuticals
  • Gradalis
  • Benitec Biopharma

 

Table of Contents

 

  1. PREFACE

 

  1. EXECUTIVE SUMMARY

 

  1. INTRODUCTION

 

  1. COMPETITIVE LANDSCAPE

 

  1. COMPANY COMPETITIVENESS ANALYSIS

 

  1. LATE STAGE RNAi THERAPEUTICS

 

  1. TECHNOLOGY PLATFORMS AND DELIVERY SYSTEMS

 

  1. KEY THERAPEUTIC INDICATIONS

 

  1. CLINICAL TRIAL ANALYSIS

 

  1. PATENT ANALYSIS

 

  1. RECENT PARTNERSHIPS

 

  1. FUNDING AND INVESTMENT ANALYSIS

 

  1. PROMOTIONAL ANALYSIS

 

  1. MARKET SIZING AND OPPORTUNITY ANALYSIS

 

  1. RNAi IN DIAGNOSTICS

 

  1. SERVICE PROVIDERS FOR RNAi THERAPEUTICS

 

  1. SWOT ANALYSIS

 

  1. CONCLUSION

 

  1. INTERVIEW TRANSCRIPT(S)

 

  1. APPENDIX 1: TABULATED DATA

 

  1. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/rnai-therapeutics-market-2nd-edition-2019-2030/278.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

Article Categories:
HEALTH

Leave a Comment